Product Description
Teprotumumab-trbw injection is used to treat thyroid eye disease (TED; Graves' eye disease; a disorder in which the immune system causes inflammation and swelling behind the eye). Teprotumumab-trbw is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in the body that causes inflammation in the eye. (Sourced from: https://medlineplus.gov/druginfo/meds/a620025.html)
Mechanisms of Action: IGF Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: Fast Track - Prostate Cancer *
Approval Status: Approved
Approved Countries: Greece | United States
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Canada, France, Germany, Italy, Japan, Poland, South Korea, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Graves Disease|Graves Ophthalmopathy|Thyroid Eye Disease
Phase 2: Prostate Cancer
Phase 1: Neuromyelitis Optica
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2031240294 | P3 |
Recruiting |
Thyroid Eye Disease |
2026-07-31 |
|
| jRCT2031220730 | P3 |
Recruiting |
Thyroid Eye Disease |
2026-06-30 |
|
| TEPEZZA (teprotumumab-trbw) Post-Marketing Requirement | P3 |
Active, not recruiting |
Thyroid Eye Disease |
2026-01-24 |
|
| HZNP-TEP-305 | P3 |
Recruiting |
Graves Disease|Thyroid Eye Disease|Graves Ophthalmopathy |
2025-10-15 |